Skip to search boxSkip to navigationSkip to main content

A pilot randomized, single-blind, placebo-controlled trial of traditional acupuncture for vasomotor symptoms and mechanistic pathways of menopause

  • Jeannette M. Painovich(corresponding author)
    ,
  • Chrisandra L. Shufelt
    ,
  • Ricardo Azziz
    ,
  • Yuching Yang
    ,
  • Mark O. Goodarzi
    ,
  • Glenn D. Braunstein
*Corresponding author for this work
  • Cedars-Sinai Medical Center
    ,
  • ,
  • Department of Endocrinology
    ,
  • University of Birmingham
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Abstract

OBJECTIVE: The aim of this study was to conduct a pilot study for the feasibility of planning a definitive clinical trial comparing traditional acupuncture (TA) with sham acupuncture (SA) and waiting control (WC) on menopause-related vasomotor symptoms (VMS), quality of life, and the hypothalamic-pituitary-adrenal axis in perimenopausal and postmenopausal women. METHODS: Thirty-three perimenopausal and postmenopausal women with at least seven VMS daily were randomized to TA, SA, or WC. The TA and SA groups were given three treatments per week for 12 weeks. Outcomes included the number and severity of VMS, Menopause-Specific Quality of Life Questionnaire, Beck Depression Inventory, Spielberg State-Trait Anxiety Instrument, Pittsburgh Quality Sleep Index, 24-hour urine cortisol and metabolites, and adrenocorticotropic hormone stimulation testing. RESULTS: Both the TA and SA groups demonstrated improved VMS trends compared with the WC group (Δ -3.5 ± 3.00 vs -4.1 ± 3.79 vs -1.2 ± 2.4, respectively; P = 20) and significantly improved Menopause-Specific Quality of Life Questionnaire vasomotor scores (Δ -1.5 ± 2.02 vs -1.8 ± 1.52 vs -0.3 ± 0.64, respectively; P = 0.04). There were no psychosocial group differences. Exit 24-hour urinary measures were lower in the TA versus the SA or WC group in total cortisol metabolites (4,658.9 ± 1,670.9 vs 7,735.8 ± 3,747.9 vs 5,166.0 ± 2,234.5, P = 0.03; respectively) and dehydroepiandrosterone (41.4 ± 27.46, 161.2 ± 222.77, and 252.4 ± 385.40, respectively; P = 0.05). The response data on adrenocorticotropic hormone stimulation cortisol also trended in the hypothesized direction (P = 0.17). CONCLUSIONS: Both TA and SA reduce VMS frequency and severity and improve VMS-related quality of life compared with WC; however, TA alone may impact the hypothalamic-pituitary-adrenal axis. This association is viewed as preliminary and hypothesis generating and should be explored in a large clinical trial.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 54-61 (8 pages)

Journal (Volume, Issue Number)

Menopause (Volume 19, Issue 1)

Publication milestones

  • Published - 01/2012

Publication status

Published - 01/2012

ISSN

1072-3714

Publication IDs

  • Scopus: 84655167108
  • PubMed: 21968279

Publication metrics

Metrics

Scopus
citations
SciVal
FWCI
2.10
SciVal
Author count
9
SciVal
citations
34
SciVal
Paper percentile
87
Fractional count
1
Fractional count
0.11
Fractional count
8
Fractional count
0.89
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Citation count
46
Captures
102

Funding Details

FundersFunding numbers
NIH
UL1TR000124
NCCIH
R01AT001482